Compare VRTX & MO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRTX | MO |
|---|---|---|
| Founded | 1989 | 1822 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.7B | 98.6B |
| IPO Year | 1991 | N/A |
| Metric | VRTX | MO |
|---|---|---|
| Price | $464.65 | $61.06 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 27 | 8 |
| Target Price | ★ $501.42 | $60.57 |
| AVG Volume (30 Days) | 1.4M | ★ 10.8M |
| Earning Date | 02-12-2026 | 01-29-2026 |
| Dividend Yield | N/A | ★ 6.93% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 14.22 | 5.24 |
| Revenue | $11,723,300,000.00 | ★ $20,166,000,000.00 |
| Revenue This Year | $10.93 | $1.44 |
| Revenue Next Year | $8.44 | N/A |
| P/E Ratio | $31.08 | ★ $11.67 |
| Revenue Growth | ★ 10.33 | N/A |
| 52 Week Low | $362.50 | $50.08 |
| 52 Week High | $519.68 | $68.60 |
| Indicator | VRTX | MO |
|---|---|---|
| Relative Strength Index (RSI) | 55.63 | 63.00 |
| Support Level | $429.00 | $54.70 |
| Resistance Level | $487.52 | $62.08 |
| Average True Range (ATR) | 12.79 | 1.15 |
| MACD | -2.15 | 0.55 |
| Stochastic Oscillator | 57.70 | 86.71 |
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Altria comprises Philip Morris USA, US Smokeless Tobacco, John Middleton, Horizon Innovations, and Helix Innovations. Through its tobacco subsidiaries, Altria maintains the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the US with 42% annual share in 2024. Beyond its core business, it holds an 8% interest in the world's largest brewer, Anheuser-Busch InBev and a 41% stake in cannabis manufacturer Cronos. It also acquired vaping company Njoy Holdings in 2023 and operates a joint venture with Japan Tobacco in the heated tobacco category for the US.